Stock futures are little changed Wednesday night after a steep sell-off in the prior session. Futures tied to the Dow Jones ...

Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is ...

In this week’s edition of InnovationRx, we look at the impact of Medicaid cuts, a $400 million obesity bet, a study of bias ...

Investors have been on alert since Trump first announced his plan for "reciprocal" tariffs — which he later walked back — on ...

European equities have started the week with a positive trading day, but with investors still reeling from one of the wildest ...

That's literally and not just figuratively the case: The VIX volatility index VIX has closed above 30 for the 10th consecutive session, the first time that's happened since Oct. 2022, which was the ...

Discover how China is tackling its growing obesity crisis through innovative campaigns and cultural shifts. What does this mean for the future of health in the country?

With more than half of Chinese adults now classified as overweight, health authorities are stepping up measures to get people ...

Novo Nordisk's head of commercial strategy steps ... it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest ...

Novo Nordisk has also invested in R&D in China. Back in 2012, Novo invested an additional $100 million to expand a state-of-the-art research centre in Beijing. The move allowed Novo to increase ...